Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Receives $56.00 Consensus Target Price from Brokerages

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) has been given an average recommendation of “Moderate Buy” by the nine ratings firms that are covering the company, MarketBeat Ratings reports. Four investment analysts have rated the stock with a hold recommendation and five have assigned a buy recommendation to the company. The average 12-month target price among brokerages that have updated their coverage on the stock in the last year is $56.00.

Several research firms have issued reports on AGIO. StockNews.com raised shares of Agios Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Saturday, May 10th. Scotiabank reduced their price objective on Agios Pharmaceuticals from $74.00 to $71.00 and set a “sector outperform” rating on the stock in a report on Friday, May 2nd. Finally, HC Wainwright initiated coverage on Agios Pharmaceuticals in a report on Monday, February 24th. They issued a “buy” rating and a $58.00 target price for the company.

Agios Pharmaceuticals Stock Performance

AGIO opened at $28.03 on Friday. The stock’s 50 day moving average price is $28.94 and its 200-day moving average price is $36.94. Agios Pharmaceuticals has a one year low of $23.42 and a one year high of $62.58. The stock has a market cap of $1.62 billion, a price-to-earnings ratio of 2.47 and a beta of 0.77.

Agios Pharmaceuticals (NASDAQ:AGIO) last released its earnings results on Thursday, May 1st. The biopharmaceutical company reported ($1.55) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.80) by $0.25. The business had revenue of $8.73 million for the quarter, compared to analyst estimates of $9.86 million. Agios Pharmaceuticals had a negative return on equity of 2.51% and a net margin of 1,845.92%. As a group, analysts predict that Agios Pharmaceuticals will post -6.85 earnings per share for the current fiscal year.

Insider Activity

In other Agios Pharmaceuticals news, Director Jacqualyn A. Fouse sold 7,497 shares of the firm’s stock in a transaction on Thursday, April 10th. The shares were sold at an average price of $25.90, for a total value of $194,172.30. Following the completion of the transaction, the director now owns 149,220 shares of the company’s stock, valued at approximately $3,864,798. This trade represents a 4.78% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Company insiders own 4.30% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the company. Franklin Resources Inc. acquired a new stake in Agios Pharmaceuticals during the 3rd quarter valued at approximately $1,499,000. Nordea Investment Management AB raised its position in Agios Pharmaceuticals by 3.6% during the fourth quarter. Nordea Investment Management AB now owns 220,569 shares of the biopharmaceutical company’s stock valued at $7,191,000 after acquiring an additional 7,593 shares in the last quarter. Contravisory Investment Management Inc. acquired a new position in Agios Pharmaceuticals in the fourth quarter valued at approximately $222,000. Inspire Investing LLC boosted its position in Agios Pharmaceuticals by 34.2% in the 4th quarter. Inspire Investing LLC now owns 12,384 shares of the biopharmaceutical company’s stock worth $407,000 after purchasing an additional 3,156 shares in the last quarter. Finally, KBC Group NV grew its stake in shares of Agios Pharmaceuticals by 30.5% during the 4th quarter. KBC Group NV now owns 2,615 shares of the biopharmaceutical company’s stock worth $86,000 after purchasing an additional 611 shares during the period.

About Agios Pharmaceuticals

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.